# The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

> **NCT06115603** · PHASE2 · RECRUITING · sponsor: **University of Arkansas, Fayetteville** · enrollment: 76 (estimated)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** Cannabigerol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06115603
- **Lead sponsor:** University of Arkansas, Fayetteville
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-14
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06115603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06115603, "The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06115603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*